moxifloxacin has been researched along with Chlamydia Infections in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bertholet, L; Blore, B; Brandley, J; Bull, A; Chernesky, M; Gratrix, J; Martin, I; Naidu, P; Parker, P; Plitt, S; Read, R; Scarrott, R; Shokoples, S; Singh, A; Smyczek, P; Turnbull, L | 1 |
| Detry, O; Haumann, A; Meunier, P; Meurisse, M; Ongaro, S | 1 |
| Blee, K; Evans, C; Horner, P; Muir, P; O'Mahony, C; Radcliffe, K | 1 |
| Bébéar, C; Bébéar, CM; Clerc, M; de Barbeyrac, B; Pereyre, S; Renaudin, H | 1 |
| Berger, RE | 1 |
| Hammerschlag, MR; Roblin, PM | 2 |
1 trial(s) available for moxifloxacin and Chlamydia Infections
| Article | Year |
|---|---|
Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Chlamydia Infections; Chlamydophila pneumoniae; Clarithromycin; Community-Acquired Infections; Fluoroquinolones; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Moxifloxacin; Nasopharynx; Pneumonia, Bacterial; Quinolines | 2000 |
6 other study(ies) available for moxifloxacin and Chlamydia Infections
| Article | Year |
|---|---|
Prevalence and antibiotic resistance of
Topics: Adult; Alberta; Anti-Bacterial Agents; Cervix Uteri; Chlamydia Infections; Chlamydia trachomatis; Cross-Sectional Studies; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gonorrhea; Humans; Logistic Models; Macrolides; Male; Moxifloxacin; Multivariate Analysis; Mycoplasma genitalium; Mycoplasma Infections; Neisseria gonorrhoeae; Sex Factors; Urine; Young Adult | 2017 |
Acute pelvic inflammatory disease as a rare cause of acute small bowel obstruction.
Topics: Abdomen, Acute; Acute Disease; Adult; Anti-Bacterial Agents; Chlamydia Infections; Chlamydia trachomatis; Female; Humans; Intestinal Obstruction; Intestine, Small; Laparoscopy; Metronidazole; Moxifloxacin; Pelvic Inflammatory Disease; Tomography, X-Ray Computed | 2019 |
2015 UK National Guideline on the management of non-gonococcal urethritis.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Disease Management; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Male; Metronidazole; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Practice Guidelines as Topic; United Kingdom; Urethritis | 2016 |
Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis.
Topics: Anti-Infective Agents; Aza Compounds; Chlamydia Infections; Chlamydia trachomatis; Female; Female Urogenital Diseases; Fluoroquinolones; Humans; Male; Male Urogenital Diseases; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma genitalium; Mycoplasma hominis; Mycoplasma Infections; Quinolines; Ureaplasma; Ureaplasma Infections | 2008 |
Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells.
Topics: Aza Compounds; Cell Line; Cell Movement; Chemokine CCL2; Chlamydia Infections; Chlamydophila pneumoniae; Endothelium, Vascular; Fluoroquinolones; Gatifloxacin; Humans; Interleukin-8; Monocytes; Moxifloxacin; Neutrophils; Ofloxacin; Phagocytosis; Quinolines; Stimulation, Chemical; Tumor Necrosis Factor-alpha | 2005 |
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Chlamydia Infections; Chlamydophila pneumoniae; Doxycycline; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 1998 |